Skip to content

Novavax NVAX Financing Cash Flow

Financing Cash Flow at other companies

Moderna logo
ModernaMRNA
$17M+325%
Roivant Sciences logo
Roivant SciencesROIV
$328.19M+220%
Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$601.58M+79,160%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$6.36M-31.0%
ALN
Alnylam PharmaceuticalsALNY
$15.71M-65.9%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's financing cash flow?
Novavax (NVAX) reported financing cash flow of $37.68M in Q1 2026.
How has Novavax's financing cash flow changed year-over-year?
Novavax's financing cash flow increased by 633.6% year-over-year, from -$7.06M to $37.68M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.